Now Reading: Wockhardt posts ₹107 crore profit, antibiotic business drives turnaround
-
01
Wockhardt posts ₹107 crore profit, antibiotic business drives turnaround
Wockhardt posts ₹107 crore profit, antibiotic business drives turnaround
Wockhardt returned to profit in the June quarter of FY27, reporting a net profit of ₹107 crore against a loss of ₹108 crore a year earlier. Revenue rose 26 per cent to…
The Story in Brief
Wockhardt returned to profit in the June quarter of FY27, reporting a net profit of ₹107 crore against a loss of ₹108 crore a year earlier. Revenue rose 26 per cent to ₹929 crore, and EBITDA grew 86 per cent to ₹188 crore, driven by its novel antibiotic business.
The company launched the Wockhardt Antibiotic Academy to promote antimicrobial resistance awareness and antibiotic stewardship among doctors. Wockhardt says around 10 lakh patients die annually in India from multidrug-resistant infections.
The Indian Opinion
A quick quarterly profit turnaround at Wockhardt will cheer investors, but the bigger story is antimicrobial resistance, an urgent public health crisis that rarely gets boardroom attention. The 10 lakh annual death figure, if accurate, makes this a national emergency, not just a commercial opportunity. The real test is whether Wockhardt's new antibiotics can stay effective against evolving superbugs and remain affordable for Indian hospitals that already struggle with drug costs.
Source: businesstoday.in
This story was synthesised by AI from the source linked above.
